Recently, Pfizer announced that the phase II clinical trial of ponsegromab, a monoclonal antibody targeting growth differentiation factor-15 (GDF-15), has achieved the primary endpoint. Compared with placebo, there were significant changes in weight and baseline in cancer cachexia patients receiving ponsegromab treatment with elevated GDF-15 levels. Cachexia is a common, life-threatening wasting disease that significantly affects the quality of life of cancer patients. The results of the study were presented in oral form at the European Society for Medical Oncology (ESMO) in 2024 and published in The New England Journal of Medicine. (Pfizer)
辉瑞公布Ponsegromab治疗癌症恶液质的 II 期临床研究数据
Pfizer announced the phase II clinical trial data of Ponsegromab for the treatment of cancer cachexia
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.